Ryaltris™ has been approved and is marketed in Australia, the Czech Republic, Poland, Russia, South Africa, Ukraine, the United Kingdom, and Uzbekistan. Glenmark concluded the DCP regulatory procedure in Europe in April 2021, enabling approval in 17 countries across UK and EU.